Litcius/Paper detail

Sex Differences in the Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta‐Analysis

Yucheng Yang, Liyun He, Shumeng Han, Na Yang, Yiwen Liu, Xuechen Wang, Yuxiu Li, Fan Ping, Lingling Xu, Wei Li, Huabing Zhang, Yuxiu Li

2025Journal of Diabetes53 citationsDOIOpen Access PDF

Abstract

AIM: To verify sex differences of GLP-1RAs for weight reduction. METHODS: We searched RCTs reporting weight change by sex from PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials registries. Meta-regression was performed to evaluate the association between weight reduction and sex differences. Subgroup analyses were stratified by individual GLP-1RA medications, dose, treatment duration, indication, type of control, background treatment, and baseline weight. The study protocol was registered (CRD42023480167). RESULTS: Fourteen studies covering dulaglutide, exenatide, liraglutide, semaglutide, and retatrutide were included in this study. The meta-analysis showed that females lost more weight than males (MD 1.04 kg [95% CIs 0.70-1.38]; MD 1.69% [95% CI 0.78-2.61]). The pooled results of GLP-1RAs indicated similar results (MD 0.88 kg [95% CIs 0.67-1.09]). Meta-regression illustrated that substantial weight reduction was significantly relevant to greater gender differences (β = -0.19 [95% CIs -0.29 to -0.09]). Subgroup analysis demonstrated that indications for weight reduction increased the gender difference in weight reduction (MD 4.21 kg [95% CIs 1.75-6.67]). Background treatment, dose, duration of treatment, baseline weight, and type of control had no subgroup differences in the sex difference in weight reduction of GLP-1RAs. Dulaglutide (MD 0.88 kg [95% CIs 0.63-1.12]) and semaglutide (MD 1.04 kg [95% CIs 0.45-1.63]) showed statistically significant differences in weight reduction between males and females. No gender difference was observed in the exenatide subgroup analysis. CONCLUSIONS: Females lost more weight than males when treated with GLP-1RAs for weight reduction. The sex difference in weight reduction became more pronounced as the degree of weight reduction increased. Indications for obesity could magnify this sex difference.

Topics & Concepts

ExenatideMedicineLiraglutideWeight lossDulaglutideSubgroup analysisSemaglutideMeta-analysisInternal medicineType 2 diabetesCochrane LibraryPooled analysisObesityEndocrinologyDiabetes mellitusBariatric Surgery and OutcomesDiabetes Treatment and ManagementPharmacology and Obesity Treatment